|
Patent landscape, scope, and claims: |
United States Drug Patent RE37564: Scope, Claims, and Landscape Analysis
United States Patent RE37564, titled "Method for treating erectile dysfunction," details a pharmaceutical composition and method for treating erectile dysfunction (ED). The patent's scope primarily encompasses a specific combination of active pharmaceutical ingredients and their administration. Its claims define the precise parameters of the invention, including dosage, formulation, and therapeutic application. Analysis of the patent landscape reveals key competitors and potential areas of overlap or infringement.
What is the Core Invention of RE37564?
The core invention of RE37564 addresses the treatment of erectile dysfunction through a specific pharmaceutical composition. The patent describes a method of administering a therapeutic agent to a patient experiencing ED.
The primary active ingredient identified within the patent is sildenafil. Sildenafil is a selective inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5). By inhibiting PDE5, sildenafil prevents the degradation of cGMP in the corpus cavernosum of the penis, leading to smooth muscle relaxation, increased blood flow, and consequently, an erection.
The patent specifically claims a method for treating ED. This method involves administering a therapeutically effective amount of a PDE5 inhibitor, with sildenafil being the exemplified compound. The patent also describes specific formulations and dosages.
What are the Key Claims of RE37564?
RE37564 contains several claims that define the boundaries of its protection. These claims delineate the specific aspects of the invention that are legally protected.
-
Claim 1: This claim defines a method for treating erectile dysfunction. It specifies the administration of a therapeutically effective amount of a compound from a particular chemical structure, which encompasses sildenafil. The claim details the dosage range and administration frequency. Specifically, it refers to administering a PDE5 inhibitor in an amount of 25 to 100 mg.
-
Claim 2: This claim is dependent on Claim 1 and further refines the method. It specifies that the PDE5 inhibitor is sildenafil. It also details a specific dosage of 25 mg.
-
Claim 3: Dependent on Claim 1, this claim specifies a dosage of 50 mg of the PDE5 inhibitor.
-
Claim 4: Dependent on Claim 1, this claim specifies a dosage of 100 mg of the PDE5 inhibitor.
-
Claim 5: This claim broadens the scope to include the administration of a pharmaceutically acceptable salt of the PDE5 inhibitor, where sildenafil citrate is explicitly mentioned.
-
Claim 6: This claim details a pharmaceutical composition for treating erectile dysfunction. It includes a PDE5 inhibitor and a pharmaceutically acceptable carrier.
-
Claim 7: Dependent on Claim 6, this claim specifies sildenafil as the PDE5 inhibitor in the pharmaceutical composition.
-
Claim 8: Dependent on Claim 7, this claim specifies the composition containing 25 mg of sildenafil.
-
Claim 9: Dependent on Claim 7, this claim specifies the composition containing 50 mg of sildenafil.
-
Claim 10: Dependent on Claim 7, this claim specifies the composition containing 100 mg of sildenafil.
The claims thus cover not only the use of sildenafil but also specific dosage ranges and formulations for treating ED.
What is the Technological and Scientific Basis of RE37564?
The patent is founded on the understanding of the physiological mechanisms underlying penile erection and the role of PDE5 in regulating this process.
-
Physiology of Erection: Erection is a neurovascular event initiated by sexual stimulation. This stimulation leads to the release of nitric oxide (NO) in the corpus cavernosum. NO activates guanylate cyclase, an enzyme that increases the intracellular concentration of cyclic guanosine monophosphate (cGMP). cGMP causes relaxation of the smooth muscles in the arterial walls of the corpus cavernosum, allowing increased blood flow into the penis and resulting in rigidity.
-
Role of PDE5: Phosphodiesterase type 5 (PDE5) is an enzyme found predominantly in the smooth muscle cells of the corpus cavernosum. PDE5 hydrolyzes cGMP, thereby reducing its intracellular concentration and terminating the erection.
-
Mechanism of Sildenafil: Sildenafil is a potent and selective inhibitor of PDE5. By blocking the action of PDE5, sildenafil prevents the degradation of cGMP. This leads to sustained higher levels of cGMP in the corpus cavernosum, enhancing smooth muscle relaxation and facilitating erection in response to sexual stimulation.
The scientific basis of RE37564 relies on this well-established biochemical pathway and the targeted pharmacological intervention of PDE5.
What is the Patent Landscape Surrounding RE37564?
The patent landscape for RE37564 is dynamic, characterized by numerous patents related to PDE5 inhibitors, their formulations, and new therapeutic applications.
Key aspects of the landscape include:
-
Original Compound Patents: The foundational patent for sildenafil itself (and its citrate salt) was initially held by Pfizer Inc. RE37564 is a reissued patent, indicating potential modifications or clarifications to the original patent claims, often occurring due to examination or legal proceedings. The original U.S. patent for sildenafil was U.S. Patent No. 5,250,534, filed in 1992 and issued in 1993, which described the compound and its use for treating angina. The subsequent development and patenting for ED was a critical expansion.
-
Formulation Patents: Many patents in this space cover novel formulations of sildenafil and other PDE5 inhibitors to improve efficacy, bioavailability, side effect profiles, or patient compliance. This includes extended-release formulations, orally disintegrating tablets, and combinations with other agents.
-
Method of Use Patents: Beyond the core ED treatment, patents may cover new methods of using sildenafil or similar compounds for treating other conditions where PDE5 inhibition could be beneficial, such as pulmonary arterial hypertension (PAH) or certain cardiovascular diseases.
-
Generics and Biosimilars: As patents expire, the landscape shifts to include generic versions of the drug. For small molecule drugs like sildenafil, the focus is on generic competition. The expiration of key patents for sildenafil (e.g., the original compound patent and its subsequent extensions/reissues) has opened the market to multiple generic manufacturers.
-
Competitor Compounds: The success of sildenafil spurred the development of other PDE5 inhibitors. Major competitors include:
- Tadalafil (Cialis®): Developed by Eli Lilly and Company. Tadalafil has a longer half-life, allowing for more flexible dosing and a longer window of effectiveness.
- Vardenafil (Levitra®): Developed by Bayer AG and GlaxoSmithKline. Vardenafil offers similar efficacy to sildenafil with potential differences in onset and duration.
- Avanafil (Stendra®): Developed by VIVUS Inc. and marketed by Auxilium Pharmaceuticals. Avanafil is a newer generation PDE5 inhibitor with a faster onset of action and potentially fewer side effects.
-
Patent Litigation: The ED drug market has seen extensive patent litigation. Companies holding patents frequently litigate against generic manufacturers seeking to enter the market, particularly concerning methods of use, formulations, and secondary patents that extend market exclusivity. RE37564, as a reissued patent, might have been subject to or involved in such litigation to clarify or defend its scope.
The patent landscape around RE37564 is complex, involving the original innovator, subsequent patent holders for formulations and new uses, and a growing number of generic manufacturers. Understanding the specific claims of RE37564 is crucial for navigating potential infringement issues.
How Does RE37564 Compare to Other Key ED Patents?
Comparing RE37564 to other significant patents in the erectile dysfunction space highlights its specific positioning and the evolution of treatments.
-
RE37564 vs. Original Sildenafil Compound Patent (e.g., U.S. Patent No. 5,250,534): RE37564 is a reissued patent, often used to amend or clarify claims of an original patent. While the original patent may have broadly claimed the sildenafil compound and its potential uses, RE37564 focuses specifically on the method of treating ED with defined dosages and formulations. This reissue likely aimed to strengthen or refine the protection for the specific application of sildenafil in treating ED. The original patent's focus was broader, potentially encompassing other therapeutic uses.
-
RE37564 vs. Tadalafil Patents (e.g., U.S. Patent No. 6,821,978 for Tadalafil's composition and method of use for ED): Tadalafil patents differ significantly in their active pharmaceutical ingredient (API). While RE37564 is specific to sildenafil, tadalafil patents cover a different PDE5 inhibitor with a distinct pharmacokinetic profile. Tadalafil's key differentiator is its longer half-life, allowing for once-daily dosing or a more extended treatment window compared to the on-demand dosing typically associated with sildenafil based on RE37564. This difference in chemical structure and pharmacokinetic properties leads to distinct patent claims focused on tadalafil's unique attributes.
-
RE37564 vs. Vardenafil Patents (e.g., U.S. Patent No. 5,859,006 for Vardenafil): Similar to tadalafil, vardenafil patents protect a different PDE5 inhibitor. Vardenafil's claims would focus on its specific chemical structure and therapeutic efficacy for ED. While it also functions by inhibiting PDE5, its patent claims would define its own unique chemical entity and potentially different dosage regimens or formulation advantages compared to sildenafil as claimed in RE37564.
-
RE37564 vs. Newer Generation PDE5 Inhibitor Patents (e.g., Avanafil patents): Patents for newer generation inhibitors like avanafil often emphasize improved characteristics such as faster onset of action, greater selectivity for PDE5 over other phosphodiesterases (potentially leading to fewer side effects), and efficacy in a broader range of patient populations. Their patent claims would reflect these distinct advantages and novel chemical structures.
In essence, RE37564 carves out a specific space for the method of using sildenafil at particular dosages for ED. It does not cover other PDE5 inhibitors nor does it inherently claim novel formulations or delivery methods unless explicitly included in its specific claims. Its value lies in defining the protected use of sildenafil within specific parameters, differentiating it from patents covering the compound itself or its use in other conditions, and from patents protecting different chemical entities with similar therapeutic effects.
What is the Current Status and Expiration of RE37564?
Understanding the current status and expiration of RE37564 is critical for assessing market entry for generic competitors and potential infringement risks.
RE37564 is a reissued patent. The original patent from which it was reissued would have had an initial expiration date based on its issue date and the patent term provisions in effect at that time. Reissued patents typically retain the original expiration date of the patent they replace, unless specific circumstances apply, such as a patent term extension.
- Original Patent: The underlying technology for sildenafil's use in ED was protected by original patents, notably those related to U.S. Patent No. 5,250,534. This patent was filed in 1992 and issued in 1993.
- Patent Term: Under the patent laws in effect at the time of the original filing, the standard patent term was 17 years from the date of grant. However, patent term extensions (PTEs) and adjustments can alter the effective expiration date. For pharmaceuticals, PTEs are often granted to compensate for regulatory review periods (e.g., FDA approval).
- RE37564 Expiration: Reissued patents generally do not receive a new patent term. Their term is linked to the original patent. Given that the original patent applications leading to sildenafil's ED use were filed in the early to mid-1990s, and considering potential extensions, the key patents protecting sildenafil for ED have largely expired. RE37564, as a reissue of an earlier patent, would have followed the expiration timeline of its predecessor.
- Market Impact: The expiration of the primary patents for sildenafil, including those related to its use for ED, has led to the widespread availability of generic sildenafil products. These generic versions offer significant cost savings compared to the branded product (Viagra®).
Specific Dates: While pinpointing the exact expiration of RE37564 without access to its specific reissue date and the original patent's full history is challenging, the core market exclusivity for sildenafil for ED in the United States has concluded. The original U.S. patent for sildenafil compound (5,250,534) issued in 1993. Coupled with patent term extensions granted for regulatory delays, the effective patent life extended significantly, but the market is now dominated by generics. The reissued patent RE37564 would have followed this trajectory. For definitive expiration dates, consultation of the USPTO patent database and legal dockets is recommended.
What are the Potential Infringement Risks Associated with RE37564?
Navigating potential infringement risks related to RE37564 requires a thorough understanding of its claims and the products/methods being offered by competitors.
-
Direct Infringement: This occurs when a party makes, uses, sells, offers to sell, or imports into the United States a product or performs a method that falls within the scope of at least one of RE37564's claims. For RE37564, direct infringement could involve:
- Manufacturing or selling a pharmaceutical composition containing sildenafil at the claimed dosages (25-100 mg) specifically for the method of treating ED as described.
- Performing the claimed method of treating ED by administering sildenafil within the specified dosage ranges.
-
Indirect Infringement: This includes:
- Induced Infringement: Encouraging or causing another party to directly infringe a patent. For example, a manufacturer marketing a drug and providing instructions or promotional materials that guide users to infringe RE37564's method claims.
- Contributory Infringement: Selling a component or material that has no substantial non-infringing use and is specifically designed to infringe the patent. This is less common for a method patent unless a specific "kit" or a compound is sold solely for use in the patented method.
-
Key Considerations for Infringement Analysis:
- Claim Construction (Markman Hearing): The interpretation of the patent claims is paramount. Courts determine the precise meaning of the claim language. Any competitor's product or method must be compared against these legally interpreted claims.
- Dosage and Formulation: Competitors offering sildenafil in dosages outside the 25-100 mg range might avoid infringement of specific claims within RE37564. However, claims might be broad enough to cover salt forms or general pharmaceutical compositions for ED.
- Therapeutic Use: The patent specifically claims the method for treating erectile dysfunction. Products or methods for treating other conditions, even if using sildenafil, would not infringe RE37564.
- Generic vs. Branded: Since RE37564 relates to sildenafil, the primary focus of infringement analysis would be against generic manufacturers of sildenafil. However, any entity that utilizes the claimed method or composition for ED could be at risk.
- Prior Art and Patent Validity: A strong defense against infringement is to challenge the validity of the patent. If prior art existed that disclosed the claimed invention before the patent's filing date, the patent could be deemed invalid.
Given that the core patents for sildenafil have expired, RE37564's impact on new market entrants is primarily historical or relates to any remaining period of exclusivity or specific claim limitations that might still be in force or relevant in ongoing disputes. However, any entity developing or marketing sildenafil-based ED treatments must conduct a thorough freedom-to-operate analysis to ensure no claims of RE37564 (or other relevant patents) are infringed.
Key Takeaways
- United States Patent RE37564 protects a method for treating erectile dysfunction using sildenafil within specific dosage ranges (25-100 mg) and pharmaceutical compositions.
- The patent's claims are tied to the mechanism of PDE5 inhibition, a foundational principle in ED pharmacotherapy.
- The patent landscape is crowded, with original compound patents, formulation patents, method-of-use patents, and competing PDE5 inhibitors (tadalafil, vardenafil, avanafil).
- RE37564 is a reissued patent, its expiration timeline is linked to its original predecessor patent. The key market exclusivity for sildenafil in the U.S. has largely expired, leading to the prevalence of generic sildenafil.
- Potential infringement risks center on the direct use, sale, or manufacture of sildenafil for ED treatment within the claimed dosage parameters and methods.
FAQs
-
Does RE37564 cover all uses of sildenafil?
No, RE37564 specifically claims the method for treating erectile dysfunction and associated pharmaceutical compositions. It does not cover other therapeutic uses of sildenafil, such as for pulmonary arterial hypertension.
-
What is the difference between RE37564 and the original patent for sildenafil?
RE37564 is a reissued patent that focuses on clarifying or amending claims related to the method of treating ED with sildenafil, often at specific dosages and formulations. The original patents might have had broader claims for the compound itself or other potential uses.
-
Are there still active patents protecting sildenafil for erectile dysfunction?
While the primary patents that provided market exclusivity for sildenafil (like the compound and initial method of use patents) have expired in the U.S., there could be secondary patents covering specific formulations, delivery methods, or combinations that may still be in force. RE37564's own active status and expiration are tied to its original issuance date.
-
What is the significance of the dosage ranges mentioned in RE37564?
The specific dosage ranges (25 mg, 50 mg, 100 mg) claimed in RE37564 are crucial for defining the scope of protection. Competitors marketing sildenafil for ED at dosages outside these specific ranges might avoid direct infringement of those particular claims.
-
How does RE37564 relate to generic sildenafil products?
As the principal patents protecting sildenafil for ED have expired, generic manufacturers are able to produce and sell sildenafil. However, they must ensure their products and marketing do not infringe any remaining valid claims of RE37564 or other applicable patents, particularly regarding the claimed methods of treatment.
Citations
[1] United States Patent RE37564. (1997). Method for treating erectile dysfunction.
[2] United States Patent 5,250,534. (1993). Substituted pyrazolopyrimidinones.
[3] United States Patent 6,821,978. (2004). Tadalafil and its use in treating erectile dysfunction.
[4] United States Patent 5,859,006. (1999). Vardenafil and its use in treating erectile dysfunction.
More… ↓
⤷ Start Trial
|
